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Abstract
The purpose of this study is to examine in a clinical setting a novel formu-
lation of objective functions for intensity-modulated radiotherapy treatment
plan multicriteria optimization (MCO) that we suggested in a recent study.
The proposed objective functions are extended with dynamic multileaf colli-
mator (DMLC) delivery constraints from the literature, and a tailored interior
point method is described to efficiently solve the resulting optimization for-
mulation. In a numerical planning study involving three patient cases, DMLC
plans Pareto optimal to the MCO formulation with the proposed objective func-
tions are generated. Evaluated based on pre-defined plan quality indices, these
DMLC plans are compared to conventionally generated DMLC plans. Com-
parable or superior plan quality is observed. Supported by these results, the
proposed objective functions are argued to have a potential to streamline the
planning process, since they are designed to overcome the methodological short-
comings associated with the conventional penalty-based objective functions as-
sumed to cause the current need for time-consuming trial-and-error parameter
tuning. In particular, the increased accuracy of the planning tools imposed by
the proposed objective functions has the potential to make the planning process
less complicated. These conclusions position the proposed formulation as an
alternative to existing methods for automated planning.
Keywords: Automated treatment planning, multicriteria optimization, mean-
tail-dose, objective functions
1. Introduction
Optimization of intensity-modulated radiation therapy (IMRT) treatment plans us-
ing the widely used penalty-based objective functions results in plans of high quality
in a majority of cases (see, e.g., [4, 22] for references on the conventional penalty
functions, and [5] for a general discussion on IMRT treatment planning based on
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2 Increased accuracy of planning tools through reformulated objective functions
these functions). The path towards satisfactory clinical quality, however, is not
always straight. Due to an implicit and not so clear relationship between the con-
ventional objective functions and measures of plan quality, several re-optimizations
with manually revised parameters are often needed—if not to improve the plan
quality, then to explore local variations in order to feel convinced on the optimality.
Limitations of the current planning tools are also reflected in the existence of
literature on methods for detection and/or post-processing of suboptimal plans.
For example, Appenzoller et al. [2] suggest a method to predict achievable dose-
volume histograms (DVHs) to be used as reference, and Fredriksson [10] describes a
technique to reduce the dose delivered to healthy tissue subsequent to optimization.
Fredriksson successfully improves in that sense an already optimized plan while
maintaining target coverage.
The large amount of resources spent on treatment planning has motivated the
development of strategies to automate the planning process. Automating strategies
include machine learning, with the aim of predicting planning related parameters
based on a database with previously treated patients; and computerization of plan-
ning schemes, often with the aim of mimicking the planning steps of the human
planner by enclosing the optimization in an outer automated fine-tuning loop. For
example, McIntosh and Purdie [13] and Shiraishi and Moore [20] present methods to
predict an achievable dose distribution to possibly input in a subsequent automated
plan reconstruction phase, and Wu et al. [25] and Appenzoller et al. [2] suggest
methods to predict parts of or entire achievable DVHs to support the planner’s
desicions on planning parameters. Some automating strategies have already been
implemented into clinical practice through commercial treatment planning systems
(TPSs). Yuan et al. [26] describe the machine-learning concepts of one commercially
available DVH prediction method, which has been later evaluated, e.g., in the study
by Tol et al. [21]. Gintz et al. [11] describe and evaluate a clinically available com-
puterization strategy to mimic a planning scheme that can handle a general patient
case.
The common approach of many automating strategies is to remove or largely
reduce human interaction within the planning process. A risk associated with such
an approach is “automation surprises”, causing the user to feel out of control and
leading to unnecessary cognitive load [3]. In our research, we take a different perspec-
tive on automated treatment planning. We argue that the demand for automation is
partly due to methodological shortcomings in the conventional penalty-based formu-
lation, and that resolving these issues by reformulating the objective functions have
a similar potential as other automating strategies to streamline the treatment plan-
ning process. A qualified formulation of objective functions has to offer a stronger
connection to plan quality measures and lead to tractable (e.g., convex) optimization
problems, yet without compromising performance—the plan quality achieved must
be at least comparable to that achieved from conventional planning. A streamlining
effect would then be expected as a result of eliminated or reduced trial and error
due to increased accuracy of the planning tools provided in the TPS.
In a recent fluence-based study [9], we suggest a novel formulation of objective
functions that possesses the above-mentioned properties to streamline the plan-
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ning process. We abandon the implicit penalty-function based paradigm to obtain
a stronger connection to commonly used plan quality measures, and use approx-
imations in order to achieve a convex optimization problem. The results of our
numerical planning study indicate an ability of the proposed formulation to per-
form equivalently or better (in terms of given plan quality measures) as compared
to the conventional formulation in the given fluence-based setting. As to the study
presented in this manuscript, the purpose is to strengthen our conclusions regarding
the streamlining potential of the proposed formulation by evaluation in a more clin-
ical context. To this end, deliverability constraints from the literature are added to
handle the delivery with the dynamic multileaf collimator (DMLC) technique. This
extension enables clinically accurate dose computations, and thus comparison with
DMLC plans conventionally generated using clinical TPSs.
2. Method
The method of this study is an extension of the objective functions introduced in
our previous fluence-based study [9] with the linear DMLC deliverability constraints
suggested by Papp and Unkelbach [16]; and the design of a tailored interior point
method to efficiently solve the resulting MCO formulation. In Section 2.1, we state
and give a motivation for the proposed objective functions, and review the deliv-
erbility constraints by Papp and Unkelbach in Section 2.2. Finally, in Section 2.3,
we discuss the matter of solving the entire MCO formulation. In particular, we
demonstrate the linear-algebraic steps towards achieving the tailored interior point
method, which are analogous to the derivation of the method described in [9] for
the deliverability-relaxed MCO formulation.
2.1. Formulation of MCO objective functions
The plan quality indices that we consider are those which can be deduced from
the dose-volume histograms (DVHs) of the dose distribution. Specifically, a dose-
at-volume index here refers to the dose level at a given volume fraction in the
DVH of a region of interest (ROI), such as a planning target volume (PTV) or
an organ at risk (OAR), thus corresponding to the minimum dose received by this
fraction of the particular ROI. In treatment plan optimization, doses-at-volume
for possibly several volume fractions of the ROIs are to be either minimized or
maximized, and/or kept below or above given dose bounds, to attain highest possible
(quantitative) plan quality and fulfil clinical requirements. This definition of the
general planning goal is in line with the “Plan Quality Metric” designed by Nelms
et al. [15] to unambiguously quantify and compare the plan quality of different
plans. The conventional way of mathematically formulating the planning goal is by
objective functions that penalize any deviation of the DVH curves from user-specified
reference points (see, e.g., [4, 22]). Since the connection between such penalties
and the actual dose-at-volume is implicit and not always clear, the optimization
operation might behave unexpectedly, causing a need for re-optimization and tedious
parameter tuning. On the contrary, the ideal way of formulating the planning goal
is, naturally, by objective functions that explicitly quantify the doses-at-volume
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in question. A consequence of such a choice would be an intractable optimization
problem which cannot be solved to proven optimality: the function quantifying dose-
at-volume is both non-differentiable and non-convex. The idea behind our proposed
formulation is to adopt the ideal explicit structure, by which the penalty-function
paradigm is abandoned, while replacing the dose-at-volume objective functions by
convex over- and concave underestimates. We use the mean-tail-dose functions
introduced by Romeijn et al. [19] to obtain such estimates. A brief review of the
proposed MCO formulation follows here; the full formulation is stated in Appendix A
and a detailed description is given in our previous paper [9].
Let d be a distribution of dose inside the patient geometry. Denote by D =
D(d; v, s) the function quantifying the dose-at-volume associated with the volume
fraction v of the ROI s, and by D+ = D+(d; v, s) and D− = D−(d; v, s) the func-
tions quantifying the upper and lower mean-tail-dose, respectively. The proposed
MCO formulation takes D+ as objective function to approximate the minimization
of D, and analogously the negative of D− to approximate the maximization. With
K doses-at-volume out of which q should be minimized and K − q maximized, the
formulation is
minimize
d
[
ξ1, · · · , ξq,−ξq+1, · · · ,−ξK
]T
subject to D+(d; vk, sk) ≤ ξk ≤ uk, lˆk ≤ ξk, k = 1, . . . , q,
D−(d; vk, sk) ≥ ξk ≥ lk, uˆk ≥ ξk, k = q+1, . . . ,K,
d deliverable dose distribution,
(2.1)
where auxiliary variables ξk are introduced for clarity. Hard upper and lower dose
bounds uk and lk are imposed on the mean-tail-doses via their auxiliary variable,
and should be used to exclude clinically irrelevant dose distributions. Lower and
upper dose bounds lˆk and uˆk are imposed only on the auxiliary variables, giving the
effect of removed incentives to further minimize or maximize the mean-tail-doses;
thus, lˆk and uˆk should be used to specify clinically satisfactory (or utopian) dose
levels. Alternatively, excluding the auxiliary variable from the multicriteria objective
removes all optimizing incentive and leaves only the hard dose bound for that mean-
tail-dose. Notice that the ideal formulation is obtained by simply replacing D+ and
D− with D. Since the upper and lower mean-tail-doses over- and underestimate the
dose-at-volume, i.e.,
D+(d; v, s) ≥ D(d; v, s) ≥ D−(d; v, s), for all d,
the dose-at-volume is properly controlled and guaranteed to satisfy the hard dose
bounds imposed on the mean-tail-doses. Regarding conservativeness of using the
clinical dose bounds aimed for D as upper and lower dose bounds for D+ and D−,
this is briefly discussed in Section 4.
By convexity of D+ and concavity of D−, the formulation in (2.1) is a convex
MCO formulation provided that the intended set of deliverable dose distributions is
convex (with respect to the delivery parameters). Without compromising convexity,
(2.1) can be extended with objective functions to minimize the maximum dose,
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maximize the minimum dose, or in any direction optimize the average dose. These
extensions are included in the full formulation given in Appendix A.
2.2. Modelling of DMLC deliverability
We use the formulation by Papp and Unkelbach [16] to mathematically model the
deliverability requirement in (2.1) for “sliding window” DMLC delivery. DMLC
delivery allows the collimator leaves to move during irradiation. By restricting to
unidirectional sweeps (sliding windows), Papp and Unkelbach were able to express
the resultant dose distribution using only linear transformations. This was achieved
by representing the sweeps as the sequences of time of arrival and departure of the
leaves at fixed positions (bixels) along the sweeping direction, rather than using
control-point based representations where the trajectories are given by the sequence
of the positions of the leaves at fixed points in time. Control-point based represen-
tations require in general a non-convex mapping to transform into dose distribution
(see, e.g., [23]). A brief review of the formulation by Papp and Unkelbach, with
some supplementary assumptions, follows here.
Denote by B the number of beam angles, by N the number of leaf pairs of the
MLC, and by J the number of bixels swept by each leaf pair, so that the fluence
map for each beam is defined on a rectangular N × J grid of bixels. The trajectory
of the nth leaf pair in the bth beam is defined as the sequences of departure times
lb,n,j and rb,n,j , for all bixels j, when the trailing (WLOG, the left) and the leading
(right) leaf begin traversing each bixel. Assuming that all leaves require a constant
time ∆t to traverse a bixel, the conditions for a feasible trajectory become
rb,n,j + ∆t ≤ rb,n,j+1, j = 1, . . . , J−1, (2.2a)
lb,n,j + ∆t ≤ lb,n,j+1, j = 1, . . . , J−1, (2.2b)
rb,n,j ≤ lb,n,j , j = 1, . . . , J, (2.2c)
where (2.2a) and (2.2b) prevent a leaf to depart from bixel j+1 before arriving there,
and (2.2c) prevents a trailing leaf to pass a leading leaf. The effect of assuming
constant traversing time is a halved number of DMLC variables as compared to
the original formulation by Papp and Unkelbach, who also keep track of arrival
times. The assumption reduces the set of feasible trajectories but, most importantly,
has no impact on the set of deliverable dose distributions. Further restrictions to
the trajectories can be made depending on limitations of the delivering treatment
machine or other resources. For example, Papp and Unkelbach outline how to handle
interdigitation constraints. The machine used in this study allows interdigitation,
but requires the leading and trailing leaves to always be separated by a minimum
gap corresponding to a fraction ρ ∈ (0, 1) of the bixel width. The leading leaf must
thus depart ρ∆t time units before the trailing leaf arrives,
rb,n,j+1 ≤ lb,n,j + ∆t− ρ∆t,
= lb,n,j + (1− ρ)∆t, j = 1, . . . , J−1, (2.3a)
rb,n,1 ≤ lb,n,1 − ρ∆t. (2.3b)
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Here, (2.3b) handles the case with the left-most bixel. Notice that the minimum
gap constraints (2.3) make (2.2c) redundant. We also require the entire delivery
to be completed within some maximum treatment time Tmax. Since the delivery of
beam b is completed when all trailing leaves have traversed the right-most bixel J ,
this requirement is formulated by the linear constraints
lb,n,J + ∆t ≤ Tb, n = 1, . . . , N and b = 1, . . . , B,∑
∀b
Tb ≤ Tmax, (2.4)
where Tb will be regarded as the beam-on time for beam b.
The dose distribution is determined by the time of exposure to radiation of the
bixels. As observed by Papp and Unkelbach, the exposure can be expressed linearly:
the full exposure of the bixels traversed by leaf pair n in beam b equals the time
intervals between the departure of the trailing and leading leaves,
lb,n,j − rb,n,j , j = 1, . . . , J.
We slightly extend this model by accounting for partial exposure due to MLC leakage
during the remaining portion of the beam-on time Tb,
τ (Tb − (lb,n,j − rb,n,j)) , j = 1, . . . , J,
where τ ∈ (0, 1) denotes the transmission factor. Assuming constant dose rate δ,
the beamlet weights of the fluence map are then given by
δ
(
lb,n,j − rb,n,j + τ
(
Tb − (lb,n,j − rb,n,j)
))
, j = 1, . . . , J,
and the dose distribution d (now discretized into voxels) is obtained from multipli-
cation with the dose deposition matrix P ,
d = δP
(
l − r + τ(T − (l − r))), (2.5)
where l and r are vectorizations of lb,n,j and rb,n,j , and the vector T is the appropriate
vectorization of the beam-on times (i.e., the vector of NJ repetitions of each Tb).
2.3. On solving the proposed MCO formulation
A Pareto optimal solution to (2.1) is obtained as the optimal solution to a weighted-
sum instance, where the multiple objective functions are scaled by some weight-
ing factors and accumulated into one. Different weighting factors lead to different
Pareto optimal solutions. Rockafellar and Uryasev [18] have shown that the con-
ditional value-at-risk measure—the financial counterpart to mean-tail-dose—can be
expressed as a linear program by the introduction of artificial variables. This re-
sult allows us to expand the weighted-sum instances of the DMLC deliverability
version of (2.1) into linear programs for which both extensive theory and efficient
methods are available, such as the simplex method and interior point methods (see,
e.g., [12] and [24]). The full formulation given in Appendix A takes this expanded
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form. A drawback with the expansion is largely increased problem sizes caused by
variables and constraints with voxelwise components (usually of the order of 105).
In our previous study [9], however, we demonstrate how to utilize an interior point
method to efficiently solve the deliverability-relaxed version of (2.1). The key is to
reduce the system of linear equations associated with the interior point method to
the order of number of bixels, usually implying a reduction in size by several orders
of magnitude. Fortunately, we can obtain an analogous reduction for the DMLC
deliverability version, since adding the constraints (2.2)–(2.5) does not change the
problem structure. The essential steps to reduce the system of linear equations
are summarized below; for linear-algebraic details, we refer to Section 4.A in our
previous study.
The constraint matrix of the linear program expansion is partitioned according
to voxelwise dependence; let it be denoted by(
A11 A12
A21 A22
)
,
where A22 takes the coefficients for all variables and constraints with voxelwise
components. The size of A11 mainly depends on the number of bixels, and thus
is in general several orders of magnitude smaller than A22. The system of linear
equations to be solved at each iteration of the interior point method has the form
−D1 0 AT11 AT21
0 −D2 AT12 AT22
A11 A12 D3 0
A21 A22 0 D4
∆x = rRHS,
where D1, D2, D3 and D4 are positive definite diagonal matrices containing the so-
called complementarity products (∆x and rRHS are generalized unknowns and right-
hand-sides). By a simple rearrangement, the voxelwise components are concentrated
in the bottom right quadrant:
−D1 AT11 0 AT21
A11 D3 A12 0
0 AT12 −D2 AT22
A21 0 A22 D4
∆x′ = r′RHS
(the prime indicating the appropriate permutation). Now, for our particular linear
program, we have A22 =
[
0 I
]T
; the zero and identity parts stem from constraints
associated with the maximum/minimum dose and mean-tail-dose objective func-
tions, respectively. This gives a useful structure to the voxelwise quadrant,
(−D2 AT22
A22 D4
)
=
−D2 0 I0 D4,1 0
I 0 D4,2
 , D4 = (D4,1 00 D4,2
)
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—but also to its inverse, which is identically structured and can be formed explicitly
(see Section 4.A in [9]). Both solving and multiplying using matrices with this
structure are inexpensive operations that merely amount to scaling and adding two
vectors. Therefore, the entire system can be solved in two relatively inexpensive
steps: by one solve using the Schur complement of the voxelwise quadrant, and by
one subsequent operation using the inverse of the voxelwise quadrant. The first step
is inexpensive since the Schur complement is considerably smaller than the entire
system; its size is identical to that of the top left quadrant, i.e., is of the order of
the number of bixels.
Applying an interior point method to solve the linear program expansion of (2.1)
has an advantage over a simplex method regarding the interpretation and choice of
stopping criteria. Once they are feasible, the iterates of the interior point method
provide information about the proximity to the optimal value, and the method
is usually terminated when the distance is “sufficiently small”. In the case of a
weighted-sum instance of (2.1), this stopping criterion is directly interpretable as
a dose tolerance (owing to the proposed objective functions being interpretable as
dose) and can thus be chosen as such. In our planning study presented in Section 3,
the interior point method is terminated when the objective function value is within 1
cGy from the optimal value. While this is to be inexact in a mathematical meaning
(the stopping criterion normally relating to machine precision), pushing the method
much further is not expected to be meaningful in our application.
3. Results
To examine the ability of the proposed objective functions to produce high-quality
DMLC plans, we have studied the plan quality indices obtained among DMLC
plans Pareto optimal to (2.1). DMLC plans generated using the MCO module in
RayStation [17] are used as a reference for conventional planning.
Three patient cases are considered: a prostate, a lung, and a head-and-neck
(HN) case. Their respective planning goal amounts to optimizing the three plan
quality measures shown in Table 3.1, subject to fulfilment of several PTV and OAR
dose requirements expressed in terms of dose-at-volume, average, minimum, and
maximum dose bounds. Lists of all PTV and OAR requirements are given in Ap-
pendix B. The restriction to three plan quality indices is to enable the visualization
of the obtained values in a three-dimensional coordinate system; in general, any
number of indices can be chosen. Our translation of the planning goals into tricri-
teria instances of (2.1) is straightforward: doses-at-volume are replaced with upper
and lower mean-tail-dose (average, minimum, and maximum doses are exact, see
Appendix A), their dose bounds left unaltered; and since no optimizing incentive
is needed for the PTV and OAR requirements in Appendix B, their auxiliary vari-
ables are excluded from the objective as described in Section 2. As to the analogous
set-up in RayStation of the tricriteria instances for conventional planning, besides
constraints to handle the dose bounds, three penalty-based objective functions are
used with the utopian levels lˆk and uˆk as reference points. Except for the initial
set-up according to the planning goals and constraints given in the tables, no further
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Table 3.1: Plan quality indices for the three studied patient cases. Type states the
type of index, here either the dose-at-volume (d-a-v) at the vk volume fraction or
average dose (avg). For the PTVs, a homogeneity index HIH%L% is constructed as
the difference between a low- (L) and high-percentage (H) dose-at-volume. Aim
indicates, for clarity, whether the index is subjected to minimization (↙) or to
maximization (↗). Parameters lk and uk are hard dose bounds [Gy], while lˆk and
uˆk are utopian levels [Gy] at which optimizing incentives can be removed.
Structure Type vk Aim lk, uˆk lˆk, uk
Prostate case
PTV 60 HI99%1%
{
d-a-v 99 % ↗ 57.0, 60.0 –
d-a-v 1 % ↙ – 60.0, 63.0
1-cm ring1 avg – ↙ – 0.0, 60.0
Rectum d-a-v 50 % ↙ – 0.0, 60.0
Lung case
PTV HI99%2%
{
d-a-v 99 % ↗ 49.5, 55.0 –
d-a-v 2 % ↙ – 55.0, 60.5
Lungs d-a-v 50 % ↙ – 0.0, 55.0
Heart d-a-v 10 % ↙ – 0.0, 55.0
HN case
PTV 56 HI95%20%
{
d-a-v 95 % ↗ 53.2, 56.0 –
d-a-v 20 % ↙ – 56.0, 69.3
PTV 66 HI95%5%
{
d-a-v 95 % ↗ 59.4, 66.0 –
d-a-v 5 % ↙ – 66.0, 69.3
Parotids avg – ↙ – 0.0, 66.0
human-to-TPS interaction is involved in this planning study.
A total of 34 DMLC plans Pareto optimal to (2.1) are generated for the prostate
and lung case, and a total of 13 for the computationally more expensive HN case.
The underlying objective function weights are normalized and equidistantly dis-
tributed on the triangle with corners in (1,0,0), (0,1,0), and (0,0,1). As to the
reference DMLC plans Pareto optimal to the conventional formulation, a total of 55
are generated for each case using the MCO module in RayStation. Independently
of how generated, all plans undergo final dose computation of clinical accuracy and
are then evaluated based on the three targeted plan quality indices of Table 3.1.
The outcome of this evaluation is shown in Figures 3.1–3.3, and DVHs are shown
in Figure 3.4 to provide a broader perspective on the plans with regards to dose
distribution. Figure 3.5 shows the plan quality indices in juxtaposition with the
Pareto optimal objective function values of (2.1).
Figures 3.1-3.3 play the central role in our analysis of the results, which are sim-
ilar for all three patient cases. In these figures, the generated plans are represented
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(a) (b)
Figure 3.1: Prostate case. Plan quality indices as listed in Table B.1 obtained among
the plans Pareto optimal to (2.1) (blue dots) with convex hull (blue surface), and
obtained among the reference plans Pareto optimal to the conventional formulation
(red dots). Unfilled dots correspond to plans that violate PTV constraints by more
than 1 %. The black circle marks the corner of best values, in this case of lowest
values. (a) and (b) show different angles of the 3D plot.
by their plan quality indices—i.e., not by their respective Pareto optimal objective
function values. As expected from the weak connection between the penalty-based
objective functions and the plan quality measures, the plans Pareto optimal to the
conventional formulation (red dots) appear arbitrarily scattered with this represen-
tation. In contrast, the plans Pareto optimal to (2.1) (blue dots) conform to a
non-dominated surface in a similar way as Pareto optimal values do to a Pareto
surface (we refer to a point as dominating over another point if it dominates in all
coordinates). This conformity is indicated by the fact that almost all of these plans
lie on the convex hull (blue surface). In fact, as can be observed in Figure 3.5,
the convex hull of the plan quality indices appears only rigidly shifted relative to
the convex hull of the corresponding Pareto optimal values, rather than deformed
in shape. These indications support the assumed stronger correlation between the
proposed objective functions and the plan quality measures.
As to the values obtained in Figures 3.1-3.3, none of the two sets of points
appears to in a clear way dominate the other. Dominance is particularly unclear for
the prostate case shown in Figure 3.1. However, the situation changes when violation
of constraints is taken into account; violation of PTV constraints by more than 1 %
is marked in the figures by unfilled dots. A dominance in favor of the proposed
objective functions is revealed when violating plans are ignored. For example, for
the lung case shown in Figure 3.2, the violating plans are exactly those out of the
conventionally generated plans that are not dominated. Although minor violation
is somewhat expected for all plans due to the final accurate dose computation, the
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(a) (b)
Figure 3.2: Plan quality indices obtained for the lung case, as listed in Table B.1
and labeled in Figure 3.1. (a) and (b) show different angles of the 3D plot.
violation obtained among plans generated using the conventional objective functions
is more systematic and of a larger extent. This inherent tendency of using the
conventional approach, giving solutions that sometimes fail to satisfy constraints, is
addressed and explained by Fredriksson [10], who suggests using smoother penalty
functions as a possible remedy.
Implications of the results are further discussed in Section 4.
4. Discussion
The goal of this study was to examine the streamlining potential on the planning
process of the objective functions suggested in our previous study [9] and formulated
in (2.1) when stress-tested with DMLC deliverability constraints and accurate dose
computations. The proposed objective functions are designed to offer a stronger
connection to measures of plan quality than the conventional penalty-based objective
functions, and to give tractable (convex) optimization problems. The proposed
functions are argued to have a streamlining potential if they, in addition, are able
to produce plans of at least equivalent quality as the conventional functions. The
outcome of our planning study indeed indicates such an ability.
Surprisingly, the results presented in Figures 3.1–3.3 and commented in Sec-
tion 3 were obtained despite several handicaps for the proposed formulation. One
such is the already addressed unfair advantage for the conventional formulation
of systematically violated constraints. Violated constraints theoretically give more
room to optimize the objective function values (here, to minimize the penalties),
yet, the plan quality indices obtained are comparable. Another handicap is the
fact that the dose bounds aimed for PTV and OAR doses-at-volume are imposed
unaltered on the mean-tail-doses when optimizing using the proposed formulation.
Since upper and lower mean-tail-doses over- and underestimate dose-at-volume, re-
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(a) (b)
Figure 3.3: Plan quality indices obtained for the HN case, as listed in Table B.1 and
labeled in Figure 3.1. (a) and (b) show different angles of the 3D plot.
spectively, the unaltered bounds overly restrict (i.e., narrow) the feasible region to
the optimization problem. A smaller feasible region gives less room to optimize the
objective function values, yet again, none of the two sets of plan quality indices dom-
inates the other. It seems indeed that the characterizing properties of the proposed
formulation—consistency with respect to plan quality measures, and convexity—are
able to compensate for these handicaps.
As mentioned in Section 3, no human-to-TPS interaction was involved in our
planning study except for initial set-up. The results are the outcome of optimizing
an MCO set-up based on a straightforward and systematic translation of the clinical
goals and requirements into objective functions and constraints. Re-optimizing each
of the conventionally generated plans with revised parameters (i.e., revised reference
points) could improve their quality and feasibility. The extent of this potential
improvement has not been investigated, but what can be concluded is an existing
need to re-optimize all three studied patient cases in order to meet the outcome
from using (2.1).
The positive effects of explicitness and convexity of the proposed formulation
(2.1) do not come for free. In abandoning the penalty function paradigm in favor of
these aspects, compromises have been made with regards to computational complex-
ity. The problem size of (2.1) in its expanded form is proportional to the number of
voxels, which can be contrasted to the problem size of the conventional formulation
proportional to the usually substantially smaller number of bixels. Although fast
optimization possibly becomes less important with more accurate planning tools,
running times must be reasonable to justify practical use. We have demonstrated in
Section 2.3 how to exploit the structure of (2.1) to significantly reduce the compu-
tational cost associated with solving this formulation using a tailored interior point
method. Combined with the techniques developed by Colombo and Gondzio [6] to
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(a) Prostate case. (b) Lung case. (c) HN case.
Figure 3.4: DVHs for the three patient cases and three respective structures for
which plan quality measures are optimized. The blue band covers the area spanned
by the plans Pareto optimal to (2.1), and the red band covers that spanned by
the plans Pareto optimal to the conventional formulation. The highlighted blue
histograms correspond to the plan with balanced objective function weights (i.e.,
with all weights equal to one third).
further reduce this cost, running times of the order of 5, 10, and 60 minutes per
weighted-sum instance of the prostate, lung, and HN case were required to meet
the desired optimization tolerance with our MATLAB (MathWorks, Natick, Mas-
sachusetts) implementation on an Intel Core i7 2.80 GHz computer with four cores.
We anticipate a decrease if GPUs are used.
Treatment planning is a complex task. To what extent it is complicated, how-
ever, depends on the planning tools available to support the planner in completing
that task. This distinction between the complexity of a process, and complicated
tools to handle the process is in line with the theories and experiences presented
by Andersson et al. [1]. While the latter is a consequence of shortcomings in tool
design and can (should) be avoided, complexity is something inherent that needs
to be accepted. In our research, we embrace the complexity of treatment planning
while aiming at making the planning process less complicated, specifically, by of-
fering more accurate tools, i.e., by reformulating the underlying objective functions
to more comprehensive alternatives. Another example of reducing complication
while accepting the complexity of treatment planning, is the successful [8] clinical
introduction of a posteriori MCO techniques made possible through rigorous and
extensive research (see, e.g., [4, 7, 14]). With these techniques at hand, the other-
wise tedious manual task of finding weighting factors that give a desired objective
function trade-off can be accomplished in a formalized and structured manner with-
out hiding degrees of freedom; the weighting factors indeed introduce a flexibility
to the planning process that should be available for the planner to explore. We
believe that combining MCO techniques with the proposed objective functions can
provide the skilled planner with the necessary tools to control the planning process
in an uncomplicated fashion. Future studies should be aiming at further developing
practical aspects of using the proposed formulation, in particular with regards to
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(a) Prostate case. (b) Lung case. (c) HN case.
Figure 3.5: Plan quality indices as labeled in Figures 3.1–3.3 (solid convex hull)
in juxtaposition with the corresponding Pareto optimal objective function values of
(2.1) (dotted convex hull), i.e., upper mean-tail-doses (u m-t-d), average doses (avg),
and the mean-tail-dose analogue of the homogeneity index (tHIH%L% ) (the difference
between a low-percentage (L) upper, and a high-percentage (H) lower mean-tail-
dose).
compliance with other treatment delivery techniques and with other types of plan
quality indices.
5. Conclusion
We have investigated the ability of our previously suggested formulation of objective
functions for treatment plan MCO to produce DMLC plans of plan quality compara-
ble to that of DMLC plans generated using the conventional penalty-based objective
functions. In a numerical planning study involving three patient case, DMLC plans
Pareto optimal to the proposed formulation were generated and compared to the
DMLC plans resultant from the penalty-based MCO module in RayStation. Com-
parable plan quality—or, better when accounting for the systematic violation of
constraints among conventionally generated plans—was observed when evaluating
the plans based on three pre-defined plan quality indices. Supported by these re-
sults, the proposed objective functions are argued to have a potential to streamline
the planning process, since they also are designed to overcome methodological short-
comings in the conventional objective functions that cause a need for trial and error
and time-consuming re-optimizations in the current planning process. These con-
clusions position the proposed formulation as an alternative to existing methods for
automated planning. In particular, we believe that the increased accuracy of the
planning tools imposed by the proposed objective functions is essential in making
the planning process less complicated.
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A. Full proposed formulation 17
A. Full proposed formulation
In the full version of (2.1), we include objective functions to minimize (↙) dose-
at-volume (d-a-v) (via mean-tail-dose approximation), maximum dose (max), and
average dose (avg) (given by (A.1a)–(A.1b), (A.1c), and (A.1d)), as well as to max-
imize (↗) dose-at-volume (via lower mean-tail-dose approximation), minimum dose
(min), and average dose ((A.1e)–(A.1f), (A.1g), and (A.1h)). The objective func-
tions, collected according to type and aim in index sets Kaimtype, are assumed sorted
in such a way that
K↙d-a-v ∪K↙max ∪K↙avg = {1, . . . , q}
and
K↗d-a-v ∪K↗min ∪K↗avg = {q+1, . . . ,K} .
The full proposed formulation is then given by
minimize
αk,ξk,ηk,d
[
ξ1, · · · , ξq,−ξq+1, · · · ,−ξK
]T
subject to αk +
1
vk
∑
i∈Vsk
∆ski η
k
i ≤ ξk, k ∈ K↙d-a-v, (A.1a)
ηki ≥ di − αk, ηki ≥ 0, i ∈ Vsk , k ∈ K↙d-a-v, (A.1b)
di ≤ ξk, i ∈ Vsk , k ∈ K↙max, (A.1c)∑
i∈Vsk
di ≤ ξk, k ∈ K↙avg, (A.1d)
lˆk ≤ ξk ≤ uk, k = 1, . . . , q,
αk − 1
1− vk
∑
i∈Vsk
∆ski η
k
i ≥ ξk, k ∈ K↗d-a-v, (A.1e)
ηki ≥ αk − di, ηki ≥ 0, i ∈ Vsk , k ∈ K↗d-a-v, (A.1f)
di ≥ ξk, i ∈ Vsk , k ∈ K↗min, (A.1g)∑
i∈Vsk
di ≥ ξk, k ∈ K↗avg, (A.1h)
uˆk ≥ ξk ≥ lk, k = q+1, . . . ,K,
d deliverable by linear constraints (2.2)–(2.5),
where αk and η
k are artificial variables used to linearly handle the mean-tail-dose
functions. The dose distribution d, auxiliary variables ξk, volume fraction vk, and
bounds lk, lˆk, uk, uˆk are as defined in Section 2. Moreover, Vs collects the voxels of
ROI s, and ∆si is the relative volume of s located in voxel i such that
∑
i∈Vs ∆
s
i = 1.
Notice that the constraints (A.1b), (A.1c), (A.1f), and (A.1g) and the variable ηk
have voxelwise components, as addressed in Section 2.3.
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B. List of PTV and OAR requirements
Table B.1 shows the PTV and OAR requirements for the prostate, lung and HN case
introduced in Section 3. In addition to these constraints, dose fall-off is required in
terms of average and maximum dose bounds for several ring structures at different
distances from the PTVs.
Table B.1: PTV and OAR dose requirements. Type indicates the type of criteria,
here dose-at-volume (d-a-v) at the vk volume fraction, or minimum (min), maximum
(max), or average (avg) dose. Parameters lk and uk [Gy] give the dose bounds.
Structure Type vk lk uk
Bladder d-a-v 5 % – 60.0
d-a-v 25 % – 48.6
d-a-v 50 % – 40.8
Hips d-a-v 50 % – 40.8
Penile bulb d-a-v 10 % – 48.6
d-a-v 50 % – 40.8
Rectum d-a-v 3 % – 60.0
d-a-v 15 % – 57.0
d-a-v 30 % – 52.8
PTV 60 d-a-v 50 % 60.0 –
PTV 48-60 d-a-v 50 % 48.0 –
PTV 48 d-a-v 99 % 45.6 –
max – – 66.0
(a) Prostate case criteria.
Structure Type vk lk uk
Brac. plexus d-a-v 1 cc – 53.0
Heart d-a-v 33 % – 40.0
Lungs avg – – 15.0
d-a-v 20 % – 25.0
d-a-v 30 % – 20.0
Oesophagus d-a-v 10 cc – 55.0
Cord, 5 mm d-a-v 1 cc – 44.0
Cord d-a-v 1 cc – 42.0
PTV d-a-v 95 % 52.3 –
d-a-v 50 % 55.0 –
d-a-v 5 % – 57.8
(b) Lung case criteria.
Structure Type vk lk uk
Pacemaker max – – 3.5
Cord max – – 46.0
d-a-v 1 cc – 44.0
Cord, 5 mm max – – 48.0
d-a-v 1 cc – 46.0
Brainstem max – – 54.0
d-a-v 1 cc – 52.0
Brainstem, 5 mm d-a-v 1 cc – 54.0
Brain max – – 60.0
d-a-v 1 cc – 58.0
Chiasm max – – 48.0
Chiasm, 3 mm max – – 50.0
Opt. nerves max – – 48.0
Opt. nerves, 3 mm max – – 50.0
Orbits max – – 40.0
Lenses max – – 6.0
Mandible d-a-v 1 cc – 69.3
PTV 56 d-a-v 991 % 53.2 –
avg – – 58.8
d-a-v 1 % – 69.3
PTV 66 d-a-v 99 % 59.4 –
avg – 66.0 –
d-a-v 1 % – 69.3
(c) HN case criteria.
